Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer

0

(European Society for Medical Oncology) The findings of the ALEX trial presented at the ELCC (European Lung Cancer Congress) 2018 in Geneva, Switzerland, support the use of alectinib as the new standard of care in the frontline treatment of ALK-positive lung cancer. Alectinib was found to provide longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer.

Leave A Reply

Your email address will not be published.